FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of ...
Framingham genetic medicine firm Variantyx has launched a new genome-based test for chromosomal abnormalities. The IriSight CNV Analysis tests for abnormalities potentially causing pregnancy loss or ...
Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback